Thymosin Beta-4 vs Survodutide
Side-by-side comparison of key properties, dosing, and research.
Recovery & RepairAnti-Aging & Longevity
Thymosin Beta-4GLP-1 / Weight Loss Agonists
Survodutide- Summary
- Thymosin Beta-4 is an endogenous 43-amino acid peptide that is the primary intracellular actin sequestering peptide. It promotes tissue repair, reduces inflammation, regenerates hair follicles, and protects cardiac tissue. Closely related to TB-500 (the active fragment), it is used for systemic tissue recovery and anti-aging.
- Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials demonstrated up to 18.7% body weight reduction at 46 weeks, among the highest reported for a dual agonist. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), where the glucagon component drives hepatic fat clearance.
- Half-Life
- Not well characterized; likely similar to TB-500 (~1–2 hours)
- ~7 days
- Admin Route
- SubQ, IM
- SubQ
- Research
- —
- —
- Typical Dose
- 5–10 mg
- 0.6 mg → 2.4 mg → 4.8 mg → 6 mg
- Frequency
- 2x per week (loading), then 1x per week (maintenance)
- Once weekly
- Key Benefits
- Systemic tissue repair and regeneration
- Promotes cardiac recovery after myocardial infarction
- Hair follicle regeneration and anti-hair-loss
- Anti-inflammatory (systemic)
- Wound healing acceleration
- Neuroprotection after brain injury
- Protects against ischemia-reperfusion injury
- Anti-aging at cellular level
- Synergizes powerfully with BPC-157
- Up to 18.7% body weight reduction at 46 weeks (Phase 2)
- Strong MASH activity — Phase 3 SYNCHRONIZE-NASH trials ongoing
- Reduces hepatic fat content via glucagon receptor-driven liver oxidation
- Once-weekly subcutaneous injection
- Greater weight loss potential than GLP-1 monotherapy
- Improvements in liver fibrosis markers in early data
- Side Effects
- Generally very well tolerated
- Injection site reactions
- Mild fatigue at initiation (repair signaling)
- Rare: mild inflammatory response
- +1 more
- Nausea (most common during titration)
- Vomiting
- Diarrhea
- Decreased appetite
- +3 more
- Stacks With
- —
- —